TH9507 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C221H366N72O67S | Reflects a 44-residue peptide with one N-terminal modification |
| Approximate molecular weight | 5136 Da | Sequence length and single acyl group determine the mass |
| Appearance | White to off-white lyophilized powder | Typical form of a purified synthetic peptide |
| Solubility class | Soluble in water and aqueous buffer | Peptide backbone favors aqueous dissolution |
| Common synonyms | GHRH(1-44) analogue; Egrifta | Descriptive name and approved brand name |
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Lyophilized material is typically held under refrigeration between two and eight degrees Celsius, shielded from light and ambient moisture. Peptides of this size adsorb to glass and plastic, so working procedures often call for low-binding containers and as few transfers as possible. Absorbed water during weighing shifts the apparent mass of a sample, and controlling room humidity reduces that source of error. Once dissolved, solutions are kept cold and used within the interval printed on the accompanying label or certificate. Degradation accelerates markedly in dilute aqueous form.
Identity and purity are judged through a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact peptide from truncated, oxidized, and deamidated variants, and the resulting peak-area percentages yield a purity figure. Electrospray ionization mass spectrometry confirms the expected molecular mass and can expose unanticipated modifications. Amino acid analysis and peptide mapping support sequence fidelity, while water content, pH, sterility, and bacterial endotoxin testing describe the physical and microbiological attributes of a finished lot.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Common analytical approaches include reversed-phase high-performance liquid chromatography for purity assessment and mass spectrometry for identity confirmation. Peptide mapping after enzymatic digestion can verify the expected sequence. Immunoassays may be used to measure the compound or its downstream markers, but they can cross-react with related peptides and require careful validation. Impurity profiles typically include truncated sequences, oxidized methionine residues, and residual solvents from synthesis. Each method reports a different property, so no single assay establishes overall quality.
Storage claims vary across suppliers, and published stability data for specific formulations are limited. Extrapolating from related peptides is common but not a substitute for direct measurement. For research use, documentation such as a certificate of analysis is often requested to confirm identity and purity. What constitutes an acceptable purity threshold depends on the intended application. Open questions remain about how temperature excursions during shipping affect long-term peptide integrity. Independent verification by an end user is not routinely reported.
== Function == The function of proton-coupled amino acid transporters is the transmembrane movement of amino acids and their derivatives for absorption by the luminal surface of the small intestine or digestion by intralysosomal proteins. In Drosophila models, the expression of SLC family genes that code for proton-coupled amino acid transporters is directly linked to the nutrient-dependent growth. In humans, similar expression patterns are observed and their function correlates to their location anatomically. Being located within the lamina of the small intestine allows for functional absorption of transported amino acids and derivatives. The majority of nutrient absorption takes place within this region of the intestines, and makes sense that these transporters are located throughout this tissue.
=== Monocyte activation test === The monocyte activation test (MAT) uses the monocytes in human blood in vitro to detect pyrogens. It was added to the European Pharmacopoeia in 2010 and accepted by the FDA in 2012.
=== Post-Reynolds era and the "Slugging Seventies" (1961–1980) === John Coleman started his coaching career at Essendon in 1961, thus ending the Dick Reynolds era at the club. In the same year, Essendon finished the season mid-table, and supporters were not expecting too much for the following season. However, the club blitzed the opposition in 1962, losing only two matches and finishing top of the table. Both losses were to the previous year's grand finalists. The finals posed no problems for the resurgent Dons, easily accounting for Carlton in the season's climax, winning the 1962 Premiership by 32 points. This was a remarkable result for Coleman, who, in just his second season of coaching, claimed the ultimate prize in Australian football. As so often is the case after a flag, the following two years were below standard. A further premiership in 1965 (won from 4th position on the ladder) was also unexpected due to periods of poor form during the 1965 season. The Bombers were a different club when the finals came around, but some of the credit for the improvement was given to the influence of Brian Sampson and Ted Fordham during the finals. Coleman's time as coach turned out to be much like his playing career: highly successful but cut short when he had to stand down due to health problems in 1967. Only six years later, on the eve of the 1973 season, he died of a heart attack at just 44 years of age. Following Coleman's retirement, the club experienced tough times on and off the field.
Sources: en.wikipedia.org
=== Mammalian cells === Although mammalian cells are cultured with more difficulty, are time-consuming, require more nutrients, and are significantly more costly, a protein that requires post-translational modifications must be expressed in mammalian cells to protect the clinical efficacy and fidelity of the product. However, even between mammalian cells, there are observed differences, for example differences in glycosylation between rodent and human cells. Even within one cell line, often stabilizing a cell line results in modified glycosylation patterns. The only commercially viable way to use mammalian cells as host systems is a high value end product. Common mammalian cell lines, especially in research include the COS-7 from Cercopithecus aethiops monkey, CHO from the Cricetulus griseus hamster, and the HEK293 human kidney line.
Actin filaments, the thin filaments, are the major component of the I-band and extend into the A-band. Myosin filaments, the thick filaments, are bipolar and extend throughout the A-band. They are cross-linked at the centre by the M-band. The giant protein titin (connectin) extends from the Z-line of the sarcomere, where it binds to the thick filament (myosin) system, to the M-band, where it is thought to interact with the thick filaments. Titin (and its splice isoforms) is the biggest single highly elasticated protein found in nature. It provides binding sites for numerous proteins and is thought to play an important role as sarcomeric ruler and as blueprint for the assembly of the sarcomere. Another giant protein, nebulin, is hypothesised to extend along the thin filaments and the entire I-Band. Similar to titin, it is thought to act as a molecular ruler along for thin filament assembly. Several proteins important for the stability of the sarcomeric structure are found in the Z-line as well as in the M-band of the sarcomere. Actin filaments and titin molecules are cross-linked in the Z-disc via the Z-line protein alpha-actinin. The M-band proteins myomesin as well as C-protein crosslink the thick filament system (myosins) and the M-band part of titin (the elastic filaments). The M-line also binds creatine kinase, which facilitates the reaction of ADP and phosphocreatine into ATP and creatine. The interaction between actin and myosin filaments in the A-band of the sarcomere is responsible for the muscle contraction (based on the sliding filament model).
== Development == The isopeptag was developed by dissecting the pilin protein (Spy0128) from Streptococcus pyogenes. Spy0128 contains two intramolecular isopeptide bonds, and to generate the isopeptag one of these bonds was split by removing the last β-strand in the protein.
Sources: en.wikipedia.org
As the raids were being conducted in Brussels, the Italian State Police executed two European Arrest Warrants in Italy. Maria Colleoni, Panzeri's wife, was arrested at their family home in Calusco d'Adda, near Bergamo, Italy, and his daughter, Silvia Panzeri, was arrested later that evening in Milan. Both women were transferred to a prison in Bergamo for detention. As of 14 December 2022, they had been released under house arrest to a property in Lombardy. Shortly thereafter, Italian authorities raided the Italian home of Francesco Giorgi, where an additional €20,000 in cash was confiscated. The European Arrest Warrant confirmed reports that the charges against Panzeri were related to corruption and gifts he had received from nation-states. The publication of the warrant was the first time that Morocco was implicated in the scandal. The day after the raids, on 10 December, a further search was conducted at the home of Belgian MEP Marc Tarabella, Vice Chair of the European Parliament's Delegation for relations with the Arab Peninsula. Tarabella had not yet been arrested. On 12 December 2022, it was announced that the Greek Anti-Money Laundering Authority had frozen all of Kaili's assets, as well as those of her close family members. This included her bank accounts, safes, companies, and any other financial assets. The head of the Anti-Money Laundering Authority noted that a newly established estate agency in Kolonaki, an upmarket neighbourhood of Athens, was of particular interest to the investigation.
UK Telegraph Newspaper (September 2008) - One woman dead, another critically ill after eating Death Cap fungi AmericanMushrooms.com - The Death Cap Mushroom Amanita phalloides Amanita phalloides: the death cap Amanita phalloides: Invasion of the Death Cap Key to species of Amanita Section Phalloideae from North and Central America - Amanita studies website California Fungi—Amanita phalloides Death cap in Australia - ANBG website On the Trail of the Death Cap Mushroom from National Public Radio "Amanita phalloides". The Encyclopedia of Life.
=== BLS I === The comparatively rarer BLS I, also called "HLA class I deficiency" is associated with TAP2, TAP1, or TAPBP deficiencies. TAP (Transporter associated with antigen processing) proteins are involved in pumping degraded cytosolic peptides across the endoplasmic reticulum membrane so they can bind to HLA class I. Once the peptide:HLA class I complex forms, it is transported to the membrane of the cell. However, a defect in the TAP proteins prevents pumping of peptides into the endoplasmic reticulum so no peptide:HLA class I complexes form and therefore no HLA class I is expressed on the membrane.
Sources: en.wikipedia.org
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.
It binds the growth hormone-releasing hormone receptor on anterior pituitary cells. Activation of that receptor promotes synthesis and release of growth hormone. The effect propagates through the growth hormone and insulin-like growth factor 1 axis.
Native GHRH is cleared quickly by peptidases, which limits how long it can stimulate its receptor. The added group hinders one of the primary cleavage enzymes. The practical consequence is a longer period of receptor activity per dose.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Binding stimulates cyclic AMP signaling and growth hormone secretion. This is the same receptor used by endogenous GHRH.